A Texas man has sued three friends of his ex-wife, accusing them of helping her obtain abortion medication in violation of state law after the Supreme Court overruled Roe v. Wade last year. Marcus Silva filed a wrongful death and conspiracy lawsuit in Galveston County, claiming that the three women arranged to obtain the pills and conceal their actions. Silva’s ex-wife is exempt from liability in the case, and is not a named defendant.
While it is unclear from the lawsuit why Silva’s former wife chose to terminate her pregnancy, it appears from alleged text messages that she had already planned to leave him by that point. The text messages included in the lawsuit show that the women shared information on abortion resources in Texas and discussed the possibility of traveling out of state for care. One woman shared a link and screenshots on information regarding abortion medication, noting that it could be done safely at home. Silva’s wife thanked the women for their help, and the women tried to guess how far along she was in the pregnancy before picking a day to begin the process.
Mifepristone, which was approved by the FDA more than 20 years ago to terminate a pregnancy up to 10 weeks, is taken with a second medication, misoprostol, and is highly effective. The law in Texas banning abortion after six weeks went into effect on September 1, 2022. Requests for abortion pills through resource organizations such as Aid Access skyrocketed afterwards.
Last month, an anti-abortion group filed a lawsuit in Texas in an attempt to get mifepristone off the table entirely. The group alleges that the government did not adequately evaluate mifepristone’s safety and shouldn’t have made it accessible via telehealth during the Covid pandemic. President Joe Biden’s administration has fought back, filing a response that said the benefits of mifepristone outweigh any risks. The government has also stated that not only is the drug safe, but that the “public interest would be dramatically harmed” if mifepristone is taken off the market.
Leave a Reply